Skip to main content
Premium Trial:

Request an Annual Quote

Celera Claims Progress in Establishing Operations

Premium

NORWALK, Conn.--Perkin-Elmer's third-quarter results announcement last month pointed to positive developments at its Celera Genomics group. By the end of April, Celera had 300 employees and laboratories and related facilities were almost fully built. The company's staff has begun sequencing the Drosophila melanogaster genome and the unit is cooperating with Compaq Computer to build one of the world's largest supercomputing centers. Amgen, Pharmacia & Upjohn, and Novartis Pharma have all signed five-year subscription agreements to Celera databases.

Perkin-Elmer has received shareholder approval to reorganize its corporate structure and will change its name to PE Corporation. The revamp will also result in the creation of separate securities for its PE Biosystems group and Celera.

During the quarter ended March 31, PE Biosystems entered into a lease agreement with Celera for ABI Prism 3700 DNA Analyzers. Revenues from sales of those instruments to Celera were $5.2 million for the quarter.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.